Conexiant
Login
  • JADPRO
  • The ASCO Post
  • JNCCN
JADPRO
  • From the Journal
     
    • Online First

    Issues

    • Current
    • Archive
    • Supplements

    Sections

    • Editorial
    • Research and Scholarship
    • Review Article
    • Grand Rounds
    • Practice Matters
    • Prescriber's Corner
    • Diagnostic Snapshot
    • Meeting Report
    • Meeting Abstracts
  • Topics & Conditions

    Solid Tumors

    • Breast Cancer
    • Central Nervous System Cancers
    • Colorectal Cancer
    • View All

    Hematologic Malignancies

    • Leukemia
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • View All

    Issues in Oncology

    • Cardio-Oncology
    • Genomics/Genetics
    • Clinical Trial Design
    • View All

    Supportive Care

    • Symptom Management
    • Pain Management
    • Palliative Care
    • View All

    Developmental Therapeutics

    • CAR T-Cell Therapy
    • Immunotherapy
    • View All
  • Events

    Live Events

    • JADPRO Live

    Webinars

    • JADPRO Clinical Case Series JADPRO Best Practices Summit

    Coverage

    • Newsreels
    • Meeting Hightlights
  • Education

    Educational Resources

    • Newsreels
    • Expert Conversations
    • FDA Focus
    • Patient Education
    • Roundtable Series
    • Meeting Highlights
    • Resource Centers
  • Multimedia
    • Podcasts
    • Videos
  • About
Subscribe Submission
Submissions Subscribe
JADPRO / Education / FDA Focus / Emrelis telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression

Emrelis (telisotuzumab vedotin-tllv) for NSCLC with high c-Met protein overexpression

May 14, 2025

Initial US Approval:

2025

Key Clinical Studies:

LUMINOSITY study (NCT03539536)

Drug Class/Description:

A c-Met-directed antibody and microtubule inhibitor conjugate

Indications and Usage:

EMRELIS is a c-Met-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy.

This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 

Dosage and Administration:

For intravenous infusion only.

  • The recommended dosage of EMRELIS is 1.9 mg/kg administered intravenously every 2 weeks until disease progression or unacceptable toxicity.
  • Reconstitute and further dilute EMRELIS prior to intravenous infusion. 

Dosage Forms and Strengths:

For injection: 20 mg or 100 mg of telisotuzumab vedotin-tllv as a lyophilized powder in a single-dose vial.

Contraindications:

None.

Warnings and Precautions:

  • Peripheral Neuropathy: Monitor patients for new or worsening peripheral neuropathy. Withhold, reduce the dose, or permanently discontinue EMRELIS based on the severity.
  • Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening or fatal ILD/pneumonitis may occur. Withhold or permanently discontinue EMRELIS based on the severity. 
  • Ocular Surface Disorders: Monitor patients for signs or symptoms of ocular surface disorders, including vision changes. Withhold or permanently discontinue EMRELIS based on the severity. 
  • Infusion-Related Reactions (IRR): Monitor patients for IRR. Withhold, reduce the rate of infusion, or permanently discontinue EMRELIS based on the severity. For patients who experience IRR, administer premedications prior to subsequent infusions. 
  • Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients about the potential risk to a fetus and to use effective contraception. 

Adverse Reactions:

The most common adverse reactions (≥20%) were peripheral neuropathy, fatigue, decreased appetite, and peripheral edema.

The most common Grade 3 or 4 laboratory abnormalities (≥2%) were decreased lymphocytes, increased glucose, increased alanine aminotransferase, increased gamma glutamyl transferase, decreased phosphorus, decreased sodium, decreased hemoglobin and decreased calcium.

Drug Interactions:

Strong CYP3A Inhibitors: concomitant use with EMRELIS may increase the AUC of MMAE. Monitor for increased risk of adverse reactions to EMRELIS. 

Use in Specific Populations:

  • Severe or Moderate Hepatic Impairment: Avoid use of EMRELIS.
  • Lactation: Advise not to breastfeed. 
  • Infertility: May impair fertility. 

Adapted From:

https://www.rxabbvie.com/pdf/emrelis_pi.pdf

 

 

Every health-care provider should make their own determination regarding specific safe and appropriate patient care practices, including drug dosages and indications. The provider should always consult the most recent prescribing/product information. FDA Focus information is not guaranteed to be accurate, complete, or current. JADPRO and its editors, authors, reviewers, and commentators cannot be held responsible for any liability incurred as a consequence of the application of any of the information listed within.

More From FDA Focus

Scemblix (asciminib) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase

October 29, 2024

Braftovi (encorafenib) with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

December 20, 2024

Jemperli (dostarlimab-gxly) for primary advanced or recurrent endometrial cancer

August 01, 2024

Advertisement
Current Issue
May/Jun 2025 Cover
May/Jun 2025 Cover Art
Vol 16 No 3 May/Jun 2025

Rare Diseases and Educational Tools for Advanced Practitioners

Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO

May 15, 2025

A Pilot Program Implementing an Evidence-Based Walking Plan to Improve Cancer-Related Fatigue

Jennifer D. Bernt, DNP, FNP-C, AOCNP, Rita Million, PhD, RN, PHNA-BC, CNE, COI, Nicole S. Pham, MPH Et al.

May 15, 2025

Ductal Carcinoma In Situ Non Mass Enhancement on MRI 10 Years Before Mammographic Microcalcifications

Nancy W. Stead, MD, Andria P. Caton, RN, OCN, CHPN

May 15, 2025

Table of Contents Archive
JADPRO Logo
JADPRO's Facebook Account JADPRO's X Account JADPRO's LinkedIn Account
Submissions Subscribe

About

  • About Us
  • Society
  • Terms and Conditions
  • Privacy Policy
  • Advertise With JADPRO

Membership

  • Login

Conexiant Oncology Publications

  • The ASCO Post
  • JNCCN
  • JNCCN 360

Copyright © 2024 Conexiant unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.